Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Nephrolithiasis, Calcium OxalateNephrolithiasis, Calcium Phosphate

Interventions

DRUG

Tolvaptan

Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).

DRUG

Placebo

Patients will receive daily dose at 8 AM and at 4 PM.

Trial Locations (1)

Mayo Clinic in Rochester, Rochester